Bicycle Therapeutics Limited BCYC 深 滬
已收盤 05-08 16:00:00 美东时间
4.81
-0.080
-1.64%
華盛通- 最 高4.918
- 今 開4.88
- 成交量 34.99万股
- 最 低 4.79
- 昨 收 4.89
- 總市值 3.36亿
- 52周最高 9.36
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 4.24
- 委 比 -90.34%
- 總股本 6981.12万
- 歷史最高 62.075
- 量 比 0.75
- 振 幅 2.62%
- 歷史最低 4.24
- 每 手 1
- 風險率 1.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.73) by 19.18 percent. This is a 1.14 percent increase over losses of $(0.88) per share
04-30 19:25
Bicycle Therapeutics Issues Updates From Its EphA2 Pipeline At The American Association for Cancer Research (AACR) Annual Meeting 2026
AACR Annual Meeting 2026 Data HighlightsNuzefatide pevedotin (nuzefatide), formerly BT5528, a potentially first-in-class EphA2 targeting Bicycle® Drug Conjugate (BDC®), Phase 1/2 data in combination with
04-20 19:11
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12
Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight and lowers the price target from $13 to $12.
04-08 21:29
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $24 to $15.
03-18 18:00
Bicycle Therapeutics Q4 EPS $(0.29) Beats $(1.00) Estimate, Sales $47.955M Up YoY From $3.708M
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(1.00) by 70.97 percent. This is a 61.33 percent increase over losses of $(0.75) per share
03-17 19:21
Bicycle Therapeutics Secures Long-Term Nuclear And Industry Partnerships To Support 212Pb Radiopharmaceutical Development And Commercial Supply
Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens of thousands of
2025-12-16 14:09
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Truist Securities Initiates Coverage On Bicycle Therapeutics with Hold Rating, Announces Price Target of $10
Truist Securities analyst Gregory Renza initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Hold rating and announces Price Target of $10.
2025-11-25 01:54
